Yes, agree with that. All you'd need to demonstrate would be that GNP + Oncosil was superior to GNP and you've got your market. SBRT requires specially-configured accelerators which are not present in all cancer centres. SBRT will also likely be more expensive given both the radiotherapy and the EUS fiducial placement costs.
OSL Price at posting:
12.0¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)